Related Experiment Video
Updated: Jul 10, 2026
07:22
Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
Published on: March 28, 2013
PPAR agonists and the metabolic syndrome
1Institut Pasteur de Lille, Département d'Athérosclérose, Inserm U545, Lille, France. Bart.Staels@pasteur-lille.fr
Therapie
|November 7, 2007
Summary
Peroxisome proliferator-activated receptors (PPARs) activation benefits cardiovascular health in patients with metabolic syndrome and type 2 diabetes. PPAR agonists show promise in preventing and treating atherosclerosis in high-risk individuals.
Area of Science:
- Cardiovascular medicine and metabolic disorders.
Background:
- Metabolic syndrome and type 2 diabetes significantly elevate cardiovascular disease (CVD) risk.
- Associated risk factors include dyslipidemia, insulin resistance, hypertension, inflammation, and coagulation disorders.
- Peroxisome proliferator-activated receptors (PPARs) are key regulators of vascular function and metabolism.
Purpose of the Study:
- To review the evidence on PPAR agonists' beneficial effects.
- To highlight their role in preventing and treating atherosclerosis.
- Focus on high-risk patients with metabolic syndrome and type 2 diabetes.
Main Methods:
- Review of emerging scientific literature.
- Analysis of PPAR activation pathways and their impact on gene expression.
- Examination of clinical data on PPAR agonists (fibrates, thiazolidinediones).
Main Results:
- PPAR activation improves glucose homeostasis and lipid metabolism.
- PPAR agonists demonstrate positive effects on endothelial function and inflammation.
- Evidence suggests PPAR agonists can modify atherosclerosis progression.
Conclusions:
- PPAR agonists offer therapeutic potential for atherosclerosis.
- These agents are particularly relevant for high-risk patients with metabolic syndrome and type 2 diabetes.
- Further research supports their use in CVD prevention and treatment.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:30Regulation of Food Intake
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
01:29Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...